Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target

Abstract

<p><a href="https://www.sciencedirect.com/topics/immunology-and-microbiology/systemic-lupus-erythematosus" title="Learn more about Systemic lupus erythematosus from ScienceDirect's AI-generated Topic Pages">Systemic lupus erythematosus</a> (SLE) is an autoimmune disease characterized by multiple organ inflammatory damage and wide spectrum of autoantibodies. The autoantibodies, especially anti-dsDNA and anti-Sm autoantibodies are highly specific to SLE, and participate in the <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/antigen-antibody-complex" title="Learn more about immune complex from ScienceDirect's AI-generated Topic Pages">immune complex</a> formation and inflammatory damage on multiple end-organs such as kidney, skin, and <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/central-nervous-system" title="Learn more about central nervous system from ScienceDirect's AI-generated Topic Pages">central nervous system</a> (CNS). However, the underlying mechanisms of autoantibody-induced tissue damage and <a href="https://www.sciencedirect.com/topics/immunology-and-microbiology/systemic-inflammation" title="Learn more about systemic inflammation from ScienceDirect's AI-generated Topic Pages">systemic inflammation</a> are still not fully understood. <a href="https://www.sciencedirect.com/topics/immunology-and-microbiology/single-cell-analysis" title="Learn more about Single cell analysis from ScienceDirect's AI-generated Topic Pages">Single cell analysis</a> of autoreactive B cells and <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/monoclonal-antibody" title="Learn more about monoclonal antibody from ScienceDirect's AI-generated Topic Pages">monoclonal antibody</a> screening from <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/patient" title="Learn more about patients from ScienceDirect's AI-generated Topic Pages">patients</a> with active SLE has improved our understanding on the origin of autoreactive B cells and the antigen targets of the pathogenic autoantibodies. B cell depletion <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/therapeutic-procedure" title="Learn more about therapies from ScienceDirect's AI-generated Topic Pages">therapies</a> have been widely studied in the clinics, but the development of more specific <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/therapeutic-procedure" title="Learn more about therapies from ScienceDirect's AI-generated Topic Pages">therapies</a> against the pathogenic <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/b-lymphocyte-subpopulation" title="Learn more about B cell subset from ScienceDirect's AI-generated Topic Pages">B cell subset</a> and autoantibodies with improved efficacy and safety still remain a big challenge. A more comprehensive autoantibody profiling combined with functional <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/characterization-of-autoantibody" title="Learn more about characterization of autoantibodies from ScienceDirect's AI-generated Topic Pages">characterization of autoantibodies</a> in diseases development will shed new insights on the etiology and pathogenesis of SLE and guide a specific treatment to individual SLE <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/patient" title="Learn more about patients from ScienceDirect's AI-generated Topic Pages">patients</a>.<br></p>